Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA)
- PMID: 20422035
- PMCID: PMC2857878
- DOI: 10.1371/journal.pone.0010247
Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA)
Abstract
Background: Our objective was to develop a consistent molecular definition of psoriasis. There have been several published microarray studies of psoriasis, and we compared disease-related genes identified across these different studies of psoriasis with our own in order to establish a consensus.
Methodology/principal findings: We present a psoriasis transcriptome from a group of 15 patients enrolled in a clinical study, and assessed its biological validity using a set of important pathways known to be involved in psoriasis. We also identified a key set of cytokines that are now strongly implicated in driving disease-related pathology, but which are not detected well on gene array platforms and require more sensitive methods to measure mRNA levels in skin tissues. Comparison of our transcriptome with three other published lists of psoriasis genes showed apparent inconsistencies based on the number of overlapping genes. We extended the well-established approach of Gene Set Enrichment Analysis (GSEA) to compare a new study with these other published list of differentially expressed genes (DEG) in a more comprehensive manner. We applied our method to these three published psoriasis transcriptomes and found them to be in good agreement with our study.
Conclusions/significance: Due to wide variability in clinical protocols, platform and sample handling, and subtle disease-related signals, intersection of published DEG lists was unable to establish consensus between studies. In order to leverage the power of multiple transcriptomes reported by several laboratories using different patients and protocols, more sophisticated methods like the extension of GSEA presented here, should be used in order to overcome the shortcomings of overlapping individual DEG approach.
Conflict of interest statement
Figures
Similar articles
-
Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.J Allergy Clin Immunol. 2009 Nov;124(5):1022-10.e1-395. doi: 10.1016/j.jaci.2009.08.046. J Allergy Clin Immunol. 2009. PMID: 19895991 Free PMC article. Clinical Trial.
-
Cross-study homogeneity of psoriasis gene expression in skin across a large expression range.PLoS One. 2013;8(1):e52242. doi: 10.1371/journal.pone.0052242. Epub 2013 Jan 4. PLoS One. 2013. PMID: 23308107 Free PMC article. Clinical Trial.
-
Resolved psoriasis lesions retain expression of a subset of disease-related genes.J Invest Dermatol. 2011 Feb;131(2):391-400. doi: 10.1038/jid.2010.280. Epub 2010 Sep 23. J Invest Dermatol. 2011. PMID: 20861854 Free PMC article.
-
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. doi: 10.3310/hta10460. Health Technol Assess. 2006. PMID: 17083854 Review.
-
The treatment of psoriasis with etanercept.Semin Cutan Med Surg. 2005 Mar;24(1):28-36. doi: 10.1016/j.sder.2005.01.003. Semin Cutan Med Surg. 2005. PMID: 15900796 Review.
Cited by
-
Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease.PLoS One. 2012;7(9):e44274. doi: 10.1371/journal.pone.0044274. Epub 2012 Sep 5. PLoS One. 2012. PMID: 22957057 Free PMC article.
-
Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures.J Invest Dermatol. 2022 Sep;142(9):2363-2374.e18. doi: 10.1016/j.jid.2022.03.022. Epub 2022 Apr 11. J Invest Dermatol. 2022. PMID: 35421402 Free PMC article.
-
MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast Cancer.Front Genet. 2022 Mar 21;13:857836. doi: 10.3389/fgene.2022.857836. eCollection 2022. Front Genet. 2022. PMID: 35386280 Free PMC article.
-
TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy.Sci Immunol. 2021 Nov 19;6(65):eabi8823. doi: 10.1126/sciimmunol.abi8823. Epub 2021 Nov 19. Sci Immunol. 2021. PMID: 34797693 Free PMC article.
-
Proteomics of skin proteins in psoriasis: from discovery and verification in a mouse model to confirmation in humans.Mol Cell Proteomics. 2015 Jan;14(1):109-19. doi: 10.1074/mcp.M114.042242. Epub 2014 Oct 28. Mol Cell Proteomics. 2015. PMID: 25351201 Free PMC article.
References
-
- Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, et al. Multiple-laboratory comparison of microarray platforms. Nat Methods. 2005;2:345–350. - PubMed
-
- Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J. Independence and reproducibility across microarray platforms. Nat Methods. 2005;2:337–343. - PubMed
-
- Shi LM, Perkins RG, Fang H, Tong WD. Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Current Opinion in Biotechnology. 2008;19:10–18. - PubMed
-
- Suarez-Farinas M, Magnasco MO. Comparing microarray studies. Methods Mol Biol. 2007;377:139–152. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical